Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selumetinib QTc assessment in healthy volunteers
NCT02056392Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2014
- Primary completion
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of selumetinib in solid tumor (3 arms), sponsored by AstraZeneca. Primary endpoint: Change From Baseline in QTcF at 24 hours. Started Mar 2014; status: completed.
02
Drugs
selumetinib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02056392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02056392.